Royal Bank Of Canada Reaffirms “Sector Perform” Rating for Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “sector perform” rating reiterated by research analysts at Royal Bank Of Canada in a report issued on Tuesday, Benzinga reports. They currently have a $737.00 price target on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price objective suggests a potential downside of 1.70% from the company’s previous close.

A number of other analysts have also commented on REGN. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 20th. Cantor Fitzgerald lifted their price target on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Wells Fargo & Company lifted their price target on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a research note on Friday, July 31st. Piper Sandler reduced their price target on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a research note on Thursday, July 9th. Finally, Citigroup lifted their price target on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $802.18.

Regeneron Pharmaceuticals Stock Down 0.1%

NASDAQ:REGN traded down $0.77 on Tuesday, reaching $749.74. 140,142 shares of the stock traded hands, compared to its average volume of 826,752. The company has a market capitalization of $77.19 billion, a price-to-earnings ratio of 18.53, a PEG ratio of 1.47 and a beta of 0.20. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals has a 12 month low of $541.00 and a 12 month high of $859.34. The company’s fifty day simple moving average is $782.91 and its 200 day simple moving average is $720.82.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. During the same period in the previous year, the business posted $12.81 earnings per share. The business’s revenue for the quarter was up 16.7% on a year-over-year basis. Equities analysts predict that Regeneron Pharmaceuticals will post 44.25 EPS for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $340,000.00. Following the transaction, the director owned 603 shares of the company’s stock, valued at approximately $512,550. This trade represents a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 31.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 4,146 shares of company stock worth $3,432,488. 6.97% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $5,682,636,000. Nuveen LLC boosted its position in shares of Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after purchasing an additional 835,240 shares during the period. Legal & General Group Plc bought a new position in shares of Regeneron Pharmaceuticals in the second quarter worth approximately $473,872,000. Bank of New York Mellon Corp bought a new position in shares of Regeneron Pharmaceuticals in the second quarter worth approximately $472,950,000. Finally, Deutsche Bank AG bought a new position in shares of Regeneron Pharmaceuticals in the second quarter worth approximately $323,249,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Zacks Research upgraded Regeneron from “hold” to “strong buy,” signaling improved confidence in the company’s valuation and outlook.
• Positive Sentiment: Sell-side analysts collectively rate REGN a “moderate buy,” suggesting that the recent weakness has not materially changed the broader bullish view. Regeneron Stock Rated Moderate Buy by Sell-Side Analysts
• Positive Sentiment: Regeneron’s latest reported quarter exceeded expectations, with earnings of $14.29 per share versus a $10.16 consensus estimate and revenue of $4.29 billion versus $3.82 billion expected. Revenue increased 16.7% year over year, supporting the company’s fundamental investment case.
• Neutral Sentiment: Regeneron is expected to report third-quarter results next month, giving investors a near-term catalyst to assess product demand, Eylea performance and management’s outlook. Regeneron Third-Quarter Results Preview
• Neutral Sentiment: Biohaven has begun enrolling patients in a combination study pairing BHV-1530 with Regeneron’s cancer drug Libtayo. The agreement could create additional evidence for Libtayo, although it is still an early-stage development opportunity. Regeneron Stock and Biohaven Clinical Supply Agreement
• Negative Sentiment: Kodiak Sciences reported positive Phase 3 DAYBREAK data for Zenkuda and tabirafusp-tedromer in wet age-related macular degeneration. The treatments matched Eylea on primary vision endpoints while potentially allowing dosing about every six months instead of Eylea’s roughly eight-week schedule, raising concerns about future competition and pricing pressure. Kodiak Positive Study Data
• Negative Sentiment: Royal Bank of Canada reaffirmed its “sector perform” rating and assigned a $737 price target, below the current trading level, indicating limited near-term upside in its view.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.